MedTrace Logo

Intermittent ADVOS vs. Hemodialysis in Non-intensive Care Patients With Liver Dysfunction

NCT06129617 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2023-11-13

No results posted yet for this study

Summary

In the planned randomized controlled prospective pilot study, we aim to evaluate ADVOS compared with conventional hemodialysis regarding the elimination of protein-bound toxins in patients with therapy-refractory hepatorenal syndrome.

The study will be performed in a regular non-ICU ward with a large experience in the use of the ADVOS therapy.

Conditions

  • Liver Cirrhosis
  • Kidney Failure, Acute
  • Kidney Replacement
  • Multi Organ Failure

Interventions

DEVICE

Hemodialysis

5 treatments with hemodialysis on day 1, 2, 3, 5 and 7

DEVICE

ADVOS

5 treatments with ADVOS on day 1, 2, 3, 5 and 7

Sponsors & Collaborators

  • ADVITOS GmbH München

    collaborator UNKNOWN

  • University Medical Center Mainz

    lead OTHER

Principal Investigators

  • Julia Weinmann-Menke, Prof. · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2025-06-01
Completion
2026-06-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06129617 on ClinicalTrials.gov